{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T14:37:19Z","timestamp":1769006239460,"version":"3.49.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2014,6,10]],"date-time":"2014-06-10T00:00:00Z","timestamp":1402358400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1007\/s00228-014-1706-x","type":"journal-article","created":{"date-parts":[[2014,6,10]],"date-time":"2014-06-10T17:27:51Z","timestamp":1402421271000},"page":"1021-1027","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Impact of biological therapy on spondyloarthritis"],"prefix":"10.1007","volume":"70","author":[{"given":"Nicola","family":"Maruotti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco Paolo","family":"Cantatore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,6,10]]},"reference":[{"issue":"Suppl 3","key":"1706_CR1","doi-asserted-by":"crossref","first-page":"iii8","DOI":"10.1136\/ard.61.suppl_3.iii8","volume":"61","author":"J Sieper","year":"2002","unstructured":"Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A (2002) Ankylosing spondylitis: an overview. Ann Rheum Dis 61(Suppl 3):iii8\u201318","journal-title":"Ann Rheum Dis"},{"key":"1706_CR2","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S0889-857X(21)00888-7","volume":"16","author":"MA Khan","year":"1990","unstructured":"Khan MA, van der Linden SM (1990) Ankylosing spondylitis and other spondyloarthropathies. Rheum Dis Clin North Am 16:551\u2013579","journal-title":"Rheum Dis Clin North Am"},{"issue":"6","key":"1706_CR3","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.berh.2011.11.006","volume":"25","author":"X Baraliakos","year":"2011","unstructured":"Baraliakos X, Braun J (2011) Spondyloarthritides. Best Pract Res Clin Rheumatol 25(6):825\u2013842","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"1","key":"1706_CR4","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/1529-0131(199801)41:1<58::AID-ART8>3.0.CO;2-G","volume":"41","author":"J Braun","year":"1998","unstructured":"Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Distler A, Sieper J (1998) Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 41(1):58\u201367","journal-title":"Arthritis Rheum"},{"issue":"12","key":"1706_CR5","first-page":"2622","volume":"26","author":"A Saraux","year":"1999","unstructured":"Saraux A, Guedes C, Allain J, Devauchelle V, Valls I, Lamour A, Guillemin F, Youinou P, Le Goff P (1999) Prevalence of rheumatoid arthritis and spondyloarthropathy in Brittany, France. Soci\u00e9t\u00e9 de Rhumatologie de l'Ouest. J Rheumatol 26(12):2622\u20132627","journal-title":"J Rheumatol"},{"issue":"5","key":"1706_CR6","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1002\/art.10934","volume":"48","author":"B Muche","year":"2003","unstructured":"Muche B, Bollow M, Fran\u00e7ois RJ, Sieper J, Hamm B, Braun J (2003) Anatomic structures involved in early- and latestage sacroiliitis in spondylarthritis: a detailed analysis by contrastenhanced magnetic resonance imaging. Arthritis Rheum 48(5):1374\u20131384","journal-title":"Arthritis Rheum"},{"issue":"6","key":"1706_CR7","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, van der Heijde D, Landew\u00e9 R, Listing J, Akkoc N, Brandt J, Braun J, Chou CT, Collantes-Estevez E, Dougados M, Huang F, Gu J, Khan MA, Kirazli Y, Maksymowych WP, Mielants H, S\u00f8rensen IJ, Ozgocmen S, Roussou E, Valle-O\u00f1ate R, Weber U, Wei J, Sieper J (2009) The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 68(6):777\u2013783","journal-title":"Ann Rheum Dis"},{"key":"1706_CR8","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1136\/ard.2011.151563","volume":"70","author":"D Heijde van der","year":"2011","unstructured":"van der Heijde D, Sieper J, Maksymowych WP, Dougados M, Burgos-Vargas R, Landew\u00e9 R, Rudwaleit M, Braun J (2011) 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 70:905\u2013908","journal-title":"Ann Rheum Dis"},{"key":"1706_CR9","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1590\/S0482-50042010000600005","volume":"50","author":"VF Azevedo","year":"2010","unstructured":"Azevedo VF, Paiva Edos S, Felippe LR, Moreira RA (2010) Occurrence of fibromyalgia in patients with ankylosing spondylitis. Rev Bras Reumatol 50:646\u2013650","journal-title":"Rev Bras Reumatol"},{"issue":"1","key":"1706_CR10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","volume":"73","author":"R Landew\u00e9","year":"2014","unstructured":"Landew\u00e9 R, Braun J, Deodhar A, Dougados M, Maksymowych WP, Mease PJ, Reveille JD, Rudwaleit M, van der Heijde D, Stach C, Hoepken B, Fichtner A, Coteur G, de Longueville M, Sieper J (2014) Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled phase 3 study. Ann Rheum Dis 73(1):39\u201347","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1706_CR11","first-page":"74","volume":"68","author":"IH Song","year":"2009","unstructured":"Song IH et al (2009) Major clinical response of rituximab in active TNFblocker naive patients with ankylosing spondylitis but not in TNFblocker-failure patients - an open label clinical trial. Ann Rheum Dis 68(3):74","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1706_CR12","first-page":"626","volume":"68","author":"G Nocturne","year":"2009","unstructured":"Nocturne G et al (2009) Lack of efficacy of rituximab in spondylarthropathies: data of 8 patients prospectively followed in the French AIR (\"auto-immunity and rituximab\") registry. Ann Rheum Dis 68(3):626","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1706_CR13","first-page":"623","volume":"68","author":"B Berner","year":"2009","unstructured":"Berner B et al (2009) Abatacept for therapy of spondyloarthritis due to therapy failure or contraindications of TNF-alpha antagonists. Ann Rheum Dis 68(3):623","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1706_CR14","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1136\/ard.2004.023176","volume":"64","author":"H Haibel","year":"2005","unstructured":"Haibel H, Rudwaleit M, Listing J, Sieper J (2005) Open label trial of anakinra in active ankylosing spondylitis over 24\u00a0weeks. Ann Rheum Dis 64(2):296\u2013298","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1706_CR15","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/rheumatology\/kem302","volume":"47","author":"AN Bennett","year":"2008","unstructured":"Bennett AN, Tan AL, Coates LC, Emery P, Marzo-Ortega H, McGonagle D (2008) Sustained response to anakinra in ankylosing spondylitis. Rheumatology (Oxford) 47(2):223\u2013224","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl 3","key":"1706_CR16","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1136\/annrheumdis-2012-eular.1852","volume":"71","author":"J Sieper","year":"2012","unstructured":"Sieper J, Inman RD, Badalamenti S et al (2012) Sarilumab for the treatment of ankylosing spondylitis: results of a phase 2, randomized. double-blind, placebo-controlled, international study. Ann Rheum Dis 71(Suppl 3):111","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 3","key":"1706_CR17","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1136\/annrheumdis-2012-eular.1849","volume":"71","author":"J Sieper","year":"2012","unstructured":"Sieper J, Porter-Brown B, Thompson L et al (2012) Tocilizumab is not effective for the treatment of ankylosing spondylitis: results of a phase 2, international, multicentre, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 71(Suppl 3):110","journal-title":"Ann Rheum Dis"},{"key":"1706_CR18","first-page":"W181b","volume":"63","author":"E Pathan","year":"2011","unstructured":"Pathan E et al (2011) Efficacy and safety of apremilast, an oral phosphodiesterase inhibitor, in ankylosing spondylitis. Arthritis Rheum 63:W181b","journal-title":"Arthritis Rheum"},{"issue":"9313","key":"1706_CR19","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","volume":"359","author":"J Braun","year":"2002","unstructured":"Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, Gromnica-Ihle E, Kellner H, Krause A, Schneider M, S\u00f6rensen H, Zeidler H, Thriene W, Sieper J (2002) Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicentre trial. Lancet 359(9313):1187\u20131193","journal-title":"Lancet"},{"key":"1706_CR20","first-page":"510","volume":"34","author":"X Baraliakos","year":"2007","unstructured":"Baraliakos X, Listing J, Rudwaleit M et al (2007) Safety and efficacy of readministration of infliximab after long-term continuous therapy and withdrawal in patients with ankylosing spondylitis. J Rheumatol 34:510\u2013515","journal-title":"J Rheumatol"},{"key":"1706_CR21","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1136\/ard.2007.075879","volume":"67","author":"J Braun","year":"2008","unstructured":"Braun J, Baraliakos X, Listing J et al (2008) Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5\u00a0years: evidence for different types of response. Ann Rheum Dis 67:340\u2013345","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"1706_CR22","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1093\/rheumatology\/ker194","volume":"50","author":"X Baraliakos","year":"2011","unstructured":"Baraliakos X, Listing J, Fritz C, Haibel H, Alten R, Burmester GR, Krause A, Schewe S, Schneider M, S\u00f6rensen H, Schmidt R, Sieper J, Braun J (2011) Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8\u00a0years\u2014early clinical response predicts long-term outcome. Rheumatology (Oxford) 50(9):1690\u20132699","journal-title":"Rheumatology (Oxford)"},{"key":"1706_CR23","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.20852","volume":"52","author":"D Heijde Van der","year":"2005","unstructured":"Van der Heijde D, Dijkmans B, Geusens P et al (2005) Efficacy and safety of infliximab in patients with ankylosing spondylitis. Results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 52:582\u2013591","journal-title":"Arthritis Rheum"},{"key":"1706_CR24","unstructured":"Heldmann F, Brandt J, Listing J et al (2009) European Ankylosing Spondylitis Infliximab Cohort (EASIC): long term efficacy of infliximab in patients with ankylosing spondylitis (AS) after 2\u00a0years of EASIC. Presented at the Annual Meeting of the European League Against Rheumatism. Copenhagen, Denmark; June 10\u201313, 2009"},{"issue":"4","key":"1706_CR25","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/art.24408","volume":"60","author":"N Barkham","year":"2009","unstructured":"Barkham N, Keen HI, Coates LC, O'Connor P, Hensor E, Fraser AD, Cawkwell LS, Bennett A, McGonagle D, Emery P (2009) Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthritis Rheum 60(4):946\u2013954","journal-title":"Arthritis Rheum"},{"issue":"11","key":"1706_CR26","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1002\/art.11325","volume":"48","author":"JC Davis Jr","year":"2003","unstructured":"Davis JC Jr, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, Kivitz A, Fleischmann R, Inman R, Tsuji W, Enbrel Ankylosing Spondylitis Study Group (2003) Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 48(11):3230\u20133236","journal-title":"Arthritis Rheum"},{"issue":"12","key":"1706_CR27","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1136\/ard.2006.056747","volume":"65","author":"D Heijde van der","year":"2006","unstructured":"van der Heijde D, Da Silva JC, Dougados M, Geher P, van der Horst-Bruinsma I, Juanola X, Olivieri I, Raeman F, Settas L, Sieper J, Szechinski J, Walker D, Boussuge MP, Wajdula JS, Paolozzi L, Fatenejad S, Etanercept Study 314 Investigators (2006) Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis. Ann Rheum Dis 65(12):1572\u20131577","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1706_CR28","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1136\/ard.2007.087270","volume":"68","author":"D Heijde van der","year":"2009","unstructured":"van der Heijde D, Schiff MH, Sieper J, Kivitz AJ, Wong RL, Kupper H, Dijkmans BA, Mease PJ, Davis JC Jr, ATLAS Study Group (2009) Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann Rheum Dis 68(6):922\u2013929","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1706_CR29","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/ard.2007.078139","volume":"67","author":"JC Davis Jr","year":"2008","unstructured":"Davis JC Jr, van der Heijde DM, Braun J, Dougados M, Clegg DO, Kivitz AJ, Fleischmann RM, Inman RD, Ni L, Lin SL, Tsuji WH (2008) Efficacy and safety of up to 192\u00a0weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis 67(3):346\u2013352","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1706_CR30","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1002\/art.11017","volume":"48","author":"J Brandt","year":"2003","unstructured":"Brandt J, Khariouzov A, Listing J, Haibel H, S\u00f6rensen H, Grassnickel L, Rudwaleit M, Sieper J, Braun J (2003) Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 48(6):1667\u20131675","journal-title":"Arthritis Rheum"},{"issue":"6","key":"1706_CR31","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/art.30223","volume":"63","author":"J Braun","year":"2011","unstructured":"Braun J, van der Horst-Bruinsma IE, Huang F, Burgos-Vargas R, Vlahos B, Koenig AS, Freundlich B (2011) Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. Arthritis Rheum 63(6):1543\u201351","journal-title":"Arthritis Rheum"},{"issue":"6","key":"1706_CR32","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/annrheumdis-2012-202389","volume":"72","author":"IH Song","year":"2013","unstructured":"Song IH, Wei\u00df A, Hermann KG, Haibel H, Althoff CE, Poddubnyy D, Listing J, Lange E, Freundlich B, Rudwaleit M, Sieper J (2013) Similar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after 1\u00a0year of treatment with etanercept: results from the ESTHER trial. Ann Rheum Dis 72(6):823\u2013825","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1706_CR33","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/rheumatology\/kep022","volume":"48","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, Olivieri I, Boki KA, Griep EN, J\u00e4rvinen P, Wong RL, Kron M, Kary S, Kupper H (2009) Adalimumab is effective and well tolerated in treating patients with ankylosing spondylitis who have advanced spinal fusion. Rheumatology (Oxford) 48(5):551\u2013557","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"1706_CR34","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1002\/art.23606","volume":"58","author":"H Haibel","year":"2008","unstructured":"Haibel H, Rudwaleit M, Listing J, Heldmann F, Wong RL, Kupper H, Braun J, Sieper J (2008) Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum 58(7):1981\u20131991","journal-title":"Arthritis Rheum"},{"issue":"6","key":"1706_CR35","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2012-201766","volume":"72","author":"J Sieper","year":"2013","unstructured":"Sieper J, van der Heijde D, Dougados M et al (2013) Efficacy and safety of adalimumab in patients with nonradiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis 72(6):815\u2013822","journal-title":"Ann Rheum Dis"},{"key":"1706_CR36","doi-asserted-by":"crossref","first-page":"S250","DOI":"10.1136\/annrheumdis-2011-200704","volume":"71","author":"P Mease","year":"2012","unstructured":"Mease P, Sieper J, van den Bosch F, Rahman P, Obermeyer K, Pangan AL (2012) Efficacy and safety of adalimumab in patients with peripheral spondyloarthritis: results from a phase 3 study. Ann Rheum Dis 71:S250","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"1706_CR37","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1002\/art.23969","volume":"58","author":"RD Inman","year":"2008","unstructured":"Inman RD, Davis JC Jr, Dv H, Diekman L, Sieper J, Kim SI, Mack M, Han J, Visvanathan S, Xu Z, Hsu B, Beutler A, Braun J (2008) Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 58(11):3402\u20133012","journal-title":"Arthritis Rheum"},{"issue":"10 Suppl","key":"1706_CR38","first-page":"S336","volume":"64","author":"R Landew\u00e8","year":"2012","unstructured":"Landew\u00e8 R, Rudwaleit M, van der Heijde D et al (2012) Effect of certolizumab pegol on signs and symptoms of ankylosing spondylitis and nonradiographic axial spondyloarthritis: 24\u00a0week results of a double blind randomized placebocontrolled phase 3 axial spondyloarthritis study. Arthritis Rheum 64(10 Suppl):S336","journal-title":"Arthritis Rheum"},{"key":"1706_CR39","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1002\/art.23901","volume":"58","author":"D Heijde Van der","year":"2008","unstructured":"Van der Heijde D, Landew\u00e9 R, Baraliakos X et al (2008) Ankylosing spondylitis study for the evaluation of recombinant infliximab therapy study group: radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 58:3063\u20133070","journal-title":"Arthritis Rheum"},{"issue":"5","key":"1706_CR40","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/art.23471","volume":"58","author":"D Heijde van der","year":"2008","unstructured":"van der Heijde D, Landew\u00e9 R, Einstein S, Ory P, Vosse D, Ni L, Lin SL, Tsuji W, Davis JC Jr (2008) Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 58(5):1324\u20131331","journal-title":"Arthritis Rheum"},{"key":"1706_CR41","doi-asserted-by":"crossref","first-page":"R127","DOI":"10.1186\/ar2794","volume":"11","author":"D Heijde Van der","year":"2009","unstructured":"Van der Heijde D, Salonen D, Weissman BN et al (2009) Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2\u00a0years. Arthritis Res Ther 11:R127","journal-title":"Arthritis Res Ther"},{"key":"1706_CR42","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/rheumatology\/kem166","volume":"46","author":"X Baraliakos","year":"2007","unstructured":"Baraliakos X, Listing J, Brandt J et al (2007) Radiographic progression in patients with ankylosing spondylitis after 4\u00a0years of treatment with the TNF-alpha antibody infliximab. Rheumatology 46:1450\u20131453","journal-title":"Rheumatology"},{"issue":"5","key":"1706_CR43","doi-asserted-by":"crossref","first-page":"R104","DOI":"10.1186\/ar2496","volume":"10","author":"X Baraliakos","year":"2008","unstructured":"Baraliakos X, Listing J, Rudwaleit M, Sieper J, Braun J (2008) The relationship between inflammation and new bone formation in patients with ankylosing spondylitis. Arthritis Res Ther 10(5):R104","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"1706_CR44","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1136\/ard.2004.033472","volume":"64","author":"X Baraliakos","year":"2005","unstructured":"Baraliakos X, Listing J, Rudwaleit M, Brandt J, Sieper J, Braun J (2005) Radiographic progression in patients with ankylosing spondylitis after 2\u00a0years of treatment with the tumour necrosis factor alpha antibody infliximab. Ann Rheum Dis 64(10):1462\u20131466","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1706_CR45","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1002\/art.10883","volume":"48","author":"J Braun","year":"2003","unstructured":"Braun J, Baraliakos X, Golder W, Brandt J, Rudwaleit M, Listing J, Bollow M, Sieper J, Van Der Heijde D (2003) Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum 48(4):1126\u20131136","journal-title":"Arthritis Rheum"},{"issue":"9","key":"1706_CR46","first-page":"S612","volume":"50","author":"M Rudwaleit","year":"2004","unstructured":"Rudwaleit M et al (2004) Magnetic resonance imaging (MRI) of the spine and the sacroiliac joints (SIJ) in ankylosing spondylitis (AS) before and during therapy with the anti-TNF agent etanercept. Arthritis Rheum 50(9):S612","journal-title":"Arthritis Rheum"},{"issue":"4","key":"1706_CR47","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/art.20977","volume":"52","author":"X Baraliakos","year":"2005","unstructured":"Baraliakos X, Davis J, Tsuji W, Braun J (2005) Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept. Arthritis Rheum 52(4):1216\u20131223","journal-title":"Arthritis Rheum"},{"issue":"4","key":"1706_CR48","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1136\/ard.2010.139667","volume":"70","author":"IH Song","year":"2011","unstructured":"Song IH, Hermann K, Haibel H, Althoff CE, Listing J, Burmester G, Krause A, Bohl-B\u00fchler M, Freundlich B, Rudwaleit M, Sieper J (2011) Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial. Ann Rheum Dis 70(4):590\u2013596","journal-title":"Ann Rheum Dis"},{"issue":"10 Suppl","key":"1706_CR49","first-page":"S339","volume":"64","author":"N Haroon","year":"2012","unstructured":"Haroon N, Inman R, Learch T et al (2012) Anti-TNF therapy slows radiographic progression of ankylosing spondylitis. Arthritis Rheum 64(10 Suppl):S339","journal-title":"Arthritis Rheum"},{"issue":"10","key":"1706_CR50","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/art.38070","volume":"65","author":"N Haroon","year":"2013","unstructured":"Haroon N, Inman RD, Learch TJ, Weisman MH, Lee M, Rahbar MH, Ward MM, Reveille JD, Gensler LS (2013) The impact of tumor necrosis factor \u03b1 inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum 65(10):2645\u20132654","journal-title":"Arthritis Rheum"},{"key":"1706_CR51","unstructured":"Haibel H, Rios V, Hermann KG et al (2009) No progression of chronic sacroiliac changes in patients with active, non-radiographic axial spondyloarthritis treated with adalimumab over 52\u00a0weeks [abstract 1798]. Presented at the Annual Meeting of the American College of Rheumatology. Philadelphia, PA; October 16\u201321, 2009"},{"key":"1706_CR52","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1136\/ard.2010.145946","volume":"70","author":"IH Song","year":"2011","unstructured":"Song IH, Heldmann F, Rudwaleit M et al (2011) Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. Ann Rheum Dis 70:1108\u20131110","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1706_CR53","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/art.27383","volume":"62","author":"IH Song","year":"2010","unstructured":"Song IH, Heldmann F, Rudwaleit M, Listing J, Appel H, Braun J, Sieper J (2010) Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Arthritis Rheum 62(5):1290\u20131297","journal-title":"Arthritis Rheum"},{"key":"1706_CR54","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jbspin.2011.02.018","volume":"79","author":"FK Lekpa","year":"2012","unstructured":"Lekpa FK, Farrenq V, Canou\u0390-Poitrine F et al (2012) Lack of efficacy of abatacept in axial spondylarthropathies refractory to tumor-necrosis-factor inhibition. Joint Bone Spine 79:47\u201350","journal-title":"Joint Bone Spine"},{"key":"1706_CR55","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.3899\/jrheum.120201","volume":"39","author":"D Wendling","year":"2012","unstructured":"Wendling D, Dougados M, Berenbaum F et al (2012) A nationwide series: data from the AIR Registry of the French Society of Rheumatology. J Rheumatol 39:2327\u20132331","journal-title":"J Rheumatol"},{"key":"1706_CR56","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jbspin.2010.08.004","volume":"77","author":"L Brulhart","year":"2010","unstructured":"Brulhart L, Nissen MJ, Chevallier P, Gabay C (2010) Tocilizumab in a patient with ankylosing spondylitis and Crohn\u2019s disease refractory to TNF antagonists. Joint Bone Spine 77:625\u2013626","journal-title":"Joint Bone Spine"},{"key":"1706_CR57","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.3899\/jrheum.110265","volume":"38","author":"JD Cohen","year":"2011","unstructured":"Cohen JD, Ferreira R, Jorgensen C (2011) Ankylosing spondylitis refractory to tumor necrosis factor blockade responds to tocilizumab. J Rheumatol 38:1527","journal-title":"J Rheumatol"},{"issue":"Suppl 3","key":"1706_CR58","first-page":"128","volume":"70","author":"J Dudler","year":"2011","unstructured":"Dudler J, Aubry-Rozier B (2011) Tocilizumab in axial spondylarthropathies: about 18 cases. Ann Rheum Dis 70(Suppl 3):128","journal-title":"Ann Rheum Dis"},{"key":"1706_CR59","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1186\/ar3766","volume":"14","author":"FK Lekpa","year":"2012","unstructured":"Lekpa FK, Poulain C, Wendling D et al (2012) Is IL-6 an appropriate target to treat spondyloarthritis patients refractory to anti-TNF therapy? a multicentre retrospective observational study. Arthritis Res Ther 14:R53","journal-title":"Arthritis Res Ther"},{"issue":"Suppl 3","key":"1706_CR60","first-page":"127","volume":"70","author":"D Baeten","year":"2011","unstructured":"Baeten D, Sieper J, Emery P et al (2011) The anti IL-17 A monoclonal antibody secukinumab (AIN457) showed good safety and efficacy in the treatment of active ankylosing spondylitis. Ann Rheum Dis 70(Suppl 3):127","journal-title":"Ann Rheum Dis"},{"issue":"Suppl","key":"1706_CR61","first-page":"S306","volume":"63","author":"I McInnes","year":"2011","unstructured":"McInnes I, Sieper J, Braun J et al (2011) Antiinterleukin 17A monoclonal antibody secukinumab reduces signs and symptoms of psoriatic arthritis in a 24-week multicenter, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 63(Suppl):S306","journal-title":"Arthritis Rheum"},{"issue":"Suppl","key":"1706_CR62","first-page":"S1080","volume":"64","author":"CT Ritchlin","year":"2012","unstructured":"Ritchlin CT, Gottlieb AB, McInnes IB et al (2012) Ustekinumab in active psoriatic arthritis including patients previously treated with anti-TNF agents: results of a phase 3, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 64(Suppl):S1080","journal-title":"Arthritis Rheum"},{"issue":"Suppl","key":"1706_CR63","first-page":"S1083","volume":"64","author":"A Kavanaugh","year":"2012","unstructured":"Kavanaugh A, McInnes IB, Gottlieb AB et al (2012) Ustekinumab in patient with active psoriatic arthritis: results of the phase 3, multicenter, double-blind, PSUMMIT I study. Arthritis Rheum 64(Suppl):S1083","journal-title":"Arthritis Rheum"},{"key":"1706_CR64","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/annrheumdis-2013-204248","volume":"73","author":"D Poddubnyy","year":"2014","unstructured":"Poddubnyy D, Hermann KG, Callhoff J, Listing J, Sieper J (2014) Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Ann Rheum Dis 73:817\u2013823","journal-title":"Ann Rheum Dis"},{"key":"1706_CR65","doi-asserted-by":"crossref","first-page":"3156","DOI":"10.1002\/art.34627","volume":"64","author":"G Schett","year":"2012","unstructured":"Schett G, Wollenhaupt J, Papp K et al (2012) Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 64:3156\u20133167","journal-title":"Arthritis Rheum"},{"key":"1706_CR66","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.1002\/art.34436","volume":"64","author":"A Kavanaugh","year":"2012","unstructured":"Kavanaugh A, Mease P, Gomez-Reino J et al (2012) Apremilast, an oral phosphodiesterase 4 inhibitor, I patients with psoriatic arthritis: results of a phase 3, randomized, controlled trial. Arthritis Rheum 64:4172\u20134173","journal-title":"Arthritis Rheum"},{"issue":"9","key":"1706_CR67","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1136\/annrheumdis-2012-201915","volume":"72","author":"E Pathan","year":"2013","unstructured":"Pathan E, Abraham S, Van Rossen E, Withrington R, Keat A, Charles PJ, Paterson E, Chowdhury M, McClinton C, Taylor PC (2013) Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis. Ann Rheum Dis 72(9):1475\u201380","journal-title":"Ann Rheum Dis"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-014-1706-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-014-1706-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-014-1706-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T09:07:31Z","timestamp":1746263251000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-014-1706-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,10]]},"references-count":67,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["1706"],"URL":"https:\/\/doi.org\/10.1007\/s00228-014-1706-x","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,10]]}}}